ASCO 2020 – Cholangiocarcinoma

The use of adjuvant chemoradiotherapy was associated with improved overall survival compared with chemotherapy alone in patients with resected extrahepatic cholangiocarcinoma. Read More ›

In a phase 2 trial of patients with cholangiocarcinoma and FGFR2 fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit. Read More ›

Preliminary data are reported for a phase 2, open-label multicenter study of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. Read More ›

The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review. Read More ›

This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer. Read More ›

Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer. Read More ›

Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma. Read More ›

Detection of IDH1 mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue. Read More ›

The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer. Read More ›

The response rate to the combination of ipilimumab and nivolumab in patients with advanced biliary tract cancer compared favorably to clinical trials investigating single-agent anti–PD-1 therapy. Read More ›

Page 1 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications